CombinatoRx Discovers Novel Multi-Target Mechanism for the Treatment of Hematologic Malignancies
April 14 2010 - 7:30AM
Business Wire
CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the
publication of new preclinical data in BLOOD, The Journal of the
American Society of Hematology. In the article entitled, “Adenosine
A2A receptor agonists and PDE inhibitors: a synergistic
multi-target mechanism discovered through systematic combination
screening in B-cell malignancies,” Rickles, et.al., Blood First
Edition Paper, prepublished online April 9, 2010; DOI
10.1182/blood-2009-11-252668, CombinatoRx researchers, in
collaboration with the Jerome Lipper Multiple Myeloma Center,
Dana-Farber Cancer Institute, Harvard Medical School, demonstrate
the powerful and unexpected synergistic interactions of A2A Agonist
and PDE Inhibitors as potential adjunctive therapy to
glucocorticoid (GC) containing regimens in the treatment of
multiple myeloma (MM) and other B-cell malignancies.
“Glucocorticoids are a key component of combination therapy
regimens in multiple myeloma and other hematological cancers.
However, glucocorticoid use comes with substantial dose limiting
toxicities. The ability to enhance glucocorticoid dependent effects
while sparing associated toxicities may have important implications
for the treatment of multiple myeloma and other B-cell
malignancies,” said Paul G. Richardson, MD, Clinical Director,
Jerome Lipper Center for Multiple Myeloma at Dana-Farber Cancer
Institute and Associate Professor of Medicine, Harvard Medical
School.
By deploying the CombinatoRx combination high throughput
screening (cHTS) technology to identify compounds that synergize
with GCs to inhibit the proliferation of the MM cells, researchers
were able to identify two classes of targeted agents that synergize
with GCs and quite strongly with each other. This synergy was
observed broadly across a large panel of MM and diffuse large
B-cell lymphoma (DLBCL) cell lines. Exposure of these cells to A2A
agonists and specific PDE inhibitors results in rapid synergistic
inhibition of proliferation and induction of apoptosis.
“These findings demonstrate the power of the CombinatoRx
combination high-throughput screening (cHTS) technology to rapidly
and systematically screen through thousands of single agents and
combinations to discover novel and unexpected synergy with
potential utility in a variety of proliferative diseases such as
multiple myeloma and other B-Cell malignancies,” said Mark H.N.
Corrigan, MD, President and CEO of CombinatoRx. “CombinatoRx is
continuing to leverage the power of its proprietary platform
through research collaborations with biopharmaceutical companies
such as our ongoing oncology research collaboration with
Novartis.”
About CombinatoRx
CombinatoRx, Incorporated (CRXX) develops novel drug candidates
with a focus on the treatment of pain and inflammation. The company
applies its combination drug discovery capabilities and its
selective ion-channel modulation platform to generate innovative
therapeutics. To learn more about CombinatoRx, please visit
www.combinatorx.com.
Forward-Looking Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
concerning CombinatoRx, the CombinatoRx cHTS drug discovery
technology, and the business plans of CombinatoRx. These
forward-looking statements about future expectations, plans,
objectives and prospects of CombinatoRx may be identified by words
like "believe," "expect," "may," "will," "should," "seek," or
“could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the
unproven nature of the CombinatoRx cHTS drug discovery technology,
the Company's ability to obtain additional financing or funding for
its research and development and those other risks that can be
found in the "Risk Factors" section of the Company’s annual report
on Form 10-K on file with the Securities and Exchange Commission
and the other reports that CombinatoRx periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those CombinatoRx contemplated by these
forward-looking statements. These forward looking statements
reflect management’s current views and CombinatoRx does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
(c) 2010 CombinatoRx, Incorporated. All rights reserved.
Combinatorx (NASDAQ:CRXX)
Historical Stock Chart
From May 2024 to Jun 2024
Combinatorx (NASDAQ:CRXX)
Historical Stock Chart
From Jun 2023 to Jun 2024